These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 7635970)
1. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970 [TBL] [Abstract][Full Text] [Related]
2. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I. Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788 [TBL] [Abstract][Full Text] [Related]
3. Regulation of collagen type I and biglycan mRNA levels by hormones and growth factors in normal and immortalized osteoblastic cell lines. Thiébaud D; Guenther HL; Porret A; Burckhardt P; Fleisch H; Hofstetter W J Bone Miner Res; 1994 Sep; 9(9):1347-54. PubMed ID: 7817818 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426 [TBL] [Abstract][Full Text] [Related]
5. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. Kostenuik PJ; Harris J; Halloran BP; Turner RT; Morey-Holton ER; Bikle DD J Bone Miner Res; 1999 Jan; 14(1):21-31. PubMed ID: 9893062 [TBL] [Abstract][Full Text] [Related]
6. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. Ibbotson KJ; Orcutt CM; D'Souza SM; Paddock CL; Arthur JA; Jankowsky ML; Boyce RW J Bone Miner Res; 1992 Apr; 7(4):425-32. PubMed ID: 1609630 [TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Oxlund H; Ejersted C; Andreassen TT; Tørring O; Nilsson MH Calcif Tissue Int; 1993 Dec; 53(6):394-9. PubMed ID: 8293353 [TBL] [Abstract][Full Text] [Related]
8. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. Locklin RM; Khosla S; Turner RT; Riggs BL J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918 [TBL] [Abstract][Full Text] [Related]
9. [New drugs with positive effects on bones]. Zofková I; Kanceva RL Cas Lek Cesk; 1997 Jul; 136(15):459-63. PubMed ID: 9340191 [TBL] [Abstract][Full Text] [Related]
10. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. Yee JA; Yan L; Dominguez JC; Allan EH; Martin TJ J Cell Physiol; 1993 Dec; 157(3):528-34. PubMed ID: 8253864 [TBL] [Abstract][Full Text] [Related]
11. Role of IGF-I on PTH effects on bone. Lombardi G; Di Somma C; Vuolo L; Guerra E; Scarano E; Colao A J Endocrinol Invest; 2010; 33(7 Suppl):22-6. PubMed ID: 20938222 [TBL] [Abstract][Full Text] [Related]
12. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. Hock JM; Gera I J Bone Miner Res; 1992 Jan; 7(1):65-72. PubMed ID: 1532281 [TBL] [Abstract][Full Text] [Related]
13. Bone matrix insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor (TGF)-beta1 levels in men and postmenopausal women with osteoporosis: lack of association with circulating growth factors and bone mineral density. Georgescu C; Seck T; Diel I; Minne H; Duncea I; Pfeilschifter J Rev Med Chir Soc Med Nat Iasi; 2004; 108(2):281-6. PubMed ID: 15688799 [TBL] [Abstract][Full Text] [Related]
14. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082 [TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation. Hashimoto T; Shigetomi M; Ohno T; Matsunaga T; Muramatsu K; Tanaka H; Sugiyama T; Taguchi T Calcif Tissue Int; 2007 Sep; 81(3):232-9. PubMed ID: 17674071 [TBL] [Abstract][Full Text] [Related]
16. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Tenta R; Sourla A; Lembessis P; Koutsilieris M Anticancer Res; 2006; 26(1A):283-91. PubMed ID: 16475708 [TBL] [Abstract][Full Text] [Related]
17. Anabolic effect of parathyroid hormone is not modified by supplementation with insulinlike growth factor I (IGF-I) or growth hormone in aged female rats fed an energy-restricted or ad libitum diet. Gunness M; Hock JM Bone; 1995 Feb; 16(2):199-207. PubMed ID: 7756048 [TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone (1-34) increased total body bone mass in aged female rats. Simmons HA; Pirie CM; Thompson DD; Ke HZ J Pharmacol Exp Ther; 1998 Jul; 286(1):341-4. PubMed ID: 9655878 [TBL] [Abstract][Full Text] [Related]